Sessa Capital’s Arcus Biosciences RCUS Stock Holding History

Sessa Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-181,000	Closed	-$5.71M	–	38
2022 Q1	$5.71M	Buy	+181,000	New	+$6.06M	0.27%	35

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sessa Capital's RCUS Position: Q2 2022 in Review

Sessa Capital sold out of Arcus Biosciences (RCUS) in Q2 2022, closing a stake of 181,000 shares — an estimated $5.71M sold.

Sessa Capital first reported a position in RCUS in Q1 2022 and held it in 1 quarter. The position peaked at $5.71M in Q1 2022. 173 funds tracked by Wall St. Rank hold RCUS as of Q2 2022.

Sessa Capital reported no remaining Arcus Biosciences position as of Q2 2022 after selling out during the quarter.
Sessa Capital sold 181,000 Arcus Biosciences shares in Q2 2022, an estimated $5.71M.
Sessa Capital first reported a position in Arcus Biosciences in Q1 2022 and held it in 1 quarter.
Sessa Capital's Arcus Biosciences position peaked at $5.71M in Q1 2022.
173 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2022.

Based on Sessa Capital's 13F filing for Q2 2022, filed 15 Aug 2022.